About this trial
The ketone β-hydroxybutyrate (BHB) is endogenously produced during periods of low glucose availability, serving as an alternative metabolic fuel. Beyond its role as an energy substrate, BHB acts as a pleiotropic signalling molecule, modulating various physiological processes across multiple tissues. BHB can also be ingested orally as a ketone monoester, transiently elevating plasma concentrations of BHB to a level similar to those seen following several days of fasting, thereby obviating the need for dietary manipulation. The influence of BHB on human skeletal muscle protein metabolism remains poorly understood, although emerging evidence suggests that BHB may play a role in regulating muscle protein turnover. As such, BHB supplementation may support skeletal muscle remodelling and offer therapeutic benefits, and investigating this is of considerable interest. This study will investigate the ability of oral BHB ingestion - co-ingested with protein - to stimulate skeletal muscle anabolism in young healthy adults. A dual amino acid stable isotope tracer approach will be utilised to determine postprandial (i.e., fed state) muscle protein synthesis (MPS) rates and whole-body amino acid kinetics, given BHBs systemic effects. This research will advance our understanding of the fundamental biology of exogenous ketosis and provide insight into the potential of BHB supplementation as a novel nutritional strategy to optimise muscle mass and quality.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
Body mass index (BMI) < 18.5 or > 30 kg/m2
Age < 18 or > 40
Regularly smokes
Type 2 diabetes
Trial design
Crossover
Treatments tested in this trial
Ketone Monoester (KE) and whey protein beverage
Dietary supplementKetone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate) and whey protein (0.3 g/kg)
Control
Dietary supplementPlacebo with bitter agent (Bitrex), to flavour match to ketone condition, whey protein (0.3 g/kg), and milk fat (to match the caloric content of the ketone condition).
Treatment groups
Trial outcomes
Primary outcomes
Skeletal muscle protein synthesis rates (FSR)
Skeletal muscle protein synthesis rates
Secondary outcomes
Plasma amino acid concentrations
Plasma amino acid concentrations
Whole-body phenylalanine kinetics assessed by stable isotope tracer methodology, including rate of appearance (Ra), rate of disappearance (Rd), hydroxylation rate, and net balance.
Whole-body kinetics of phenylalanine will be quantified using a primed continuous intravenous infusion of stable isotope-labelled phenylalanine and tyrosine tracers (e.g., L-\[ring-²H₅\]-phenylalanine and L-\[³-¹³C\]-tyrosine). Arterialised-venous blood samples will be collected at steady state to determine tracer enrichment in plasma. The following parameters will be calculated: Rate of appearance (Ra) of phenylalanine (μmol/kg/min), rate of disappearance (Rd) of phenylalanine (μmol/kg/min), hydroxylation rate of phenylalanine to tyrosine (μmol/kg/min) (derived from the appearance of labelled tyrosine from labelled phenylalanine), and net balance of phenylalanine (μmol/kg/min): calculated as the difference between Ra and Rd to assess overall protein balance.
Serum insulin concentrations
Serum insulin concentrations
Plasma beta hydroxybutyrate concentrations
Plasma beta hydroxybutyrate concentrations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.